⏱️ 6 min read

The Endocannabinoid System: Your Body's Natural Balancing Network

Share:

In the vast ecosystem of human physiology, few systems remain as fascinating yet under-appreciated and under-researched as the endocannabinoid system (ECS).

Discovered only in the early 1990s during research on tetrahydrocannabinol (THC)—the primary psychoactive compound in cannabis—the ECS has since emerged as a critical regulatory network that helps maintain your body’s internal balance, or homeostasis. It is fascinating that, despite our extensive understanding of the human body, a critical system for maintaining health remained undiscovered until relatively recently. The analogy would be to have had little awareness of the nervous system or the circulatory system until recent times.

It was always my goal in clinic to help patients understand more about their health so they could be as equipped as possible to make informed decisions about their treatment options and approach to healthy living. Since learning about the central role of the ECS in our health, I believe it is crucial for everyone to understand this system and make informed decisions to optimize their well-being.

In this article I share information that will help you develop a better understanding of the ECS.

Because this system is newly discovered and research continues, the information presented here is as up to date as possible. In the coming years further vital information will be learned about this system. This will further improve our opportunity to live as healthy as possible.

Table of Contents

Endocannabinoid System 101: The Basics

Functions of the Endocannabinoid System

The ECS and Plant Interactions: Beyond Cannabis

Supporting Your Endocannabinoid System Naturally

Endocannabinoid System 101: The Basics

The endocannabinoid system isn’t just for cannabis users—it’s an integral part of everyone’s physiology. Think of it as your body’s natural balancing mechanism, constantly working behind the scenes to regulate essential functions like sleep, appetite, pain, mood, and immune response.

Dr. Ethan Russo, a neurologist and medical researcher, describes the ECS as “the most widespread and versatile signaling system in the body,” noting that it plays a role in “virtually all human diseases.”

The Three Core Components

Like many well-designed systems, the ECS consists of three primary elements:

• Endocannabinoids: These naturally occurring, lipid-based neurotransmitters, also known as endogenous cannabinoids, are produced by your own body and play crucial roles in various bodily functions. The two most well-studied endocannabinoids are anandamide (AEA)—often called the “bliss molecule”—and 2-arachidonoylglycerol (2-AG).
• Cannabinoid Receptors: These receptors are found throughout your body and serve as landing sites for endocannabinoids. The two main types are:
  
  - CB1 receptors: Primarily located in the brain and central nervous system, affecting pain perception, memory, and motor function.
  
  - CB2 receptors: Predominantly found in immune cells, regulating inflammation and immune responses.
• Enzymes: These proteins are responsible for creating and breaking down endocannabinoids once they’ve served their purpose:
  
  - Fatty acid amide hydrolase (FAAH): Breaks down anandamide
  
  - Monoacylglycerol lipase (MAGL): Degrades 2-AG
  

It is worth noting that cannabinoid receptors can also be found in many locations throughout the body, and research continues to uncover their functions. It is also important to note here that there are two forms of cannabinoids:

1. Endogeneous cannabinoids, as we described, are naturally produced in the human body.

2. Exogenous cannabinoids are better known. They are the plan based version of cannabinoids that when ingested or applied to the skin also bind to the ECS.These molecules also influence the complex regulation of many functions throughout the body.

The fact that both forms of cannabinoids can influence the ECS is why molecules like CBD offer significant potential to help regulate many functions related to health and wellness.

Endocannabinoid Receptors and Signaling

Endocannabinoid receptors are a class of G protein-coupled receptors that play a crucial role in the endocannabinoid system. The two primary cannabinoid receptors are CB1 and CB2, which are found in different parts of the body. CB1 receptors are primarily located in the central nervous system (CNS), including the brain and spinal cord, while CB2 receptors are found in the peripheral nervous system (PNS) and immune cells.

When an endocannabinoid binds to a cannabinoid receptor, it triggers a signaling cascade that can affect various physiological processes. The binding of an endocannabinoid to a CB1 receptor can inhibit the release of neurotransmitters, such as dopamine and glutamate, which can lead to changes in mood, appetite, and pain perception. The binding of an endocannabinoid to a CB2 receptor can modulate the immune response and reduce inflammation.

Endocannabinoid signaling is a complex process that involves the activation of various signaling pathways, including the adenylyl cyclase pathway, the phospholipase C pathway, and the mitogen-activated protein kinase (MAPK) pathway. These pathways can lead to changes in gene expression, protein synthesis, and cellular behavior.

Endocannabinoid Synthesis and Release

Endocannabinoids are synthesized from fatty acids and released from cells in response to various stimuli, including changes in intracellular calcium levels, neuronal excitability, and immune cell activation. The synthesis of endocannabinoids involves the action of several enzymes, including phospholipase D, diacylglycerol lipase, and fatty acid amide hydrolase (FAAH).

The release of endocannabinoids can be triggered by various mechanisms, including the activation of G protein-coupled receptors, the release of neurotransmitters, and the activation of immune cells. Once released, endocannabinoids can bind to cannabinoid receptors on nearby cells, triggering a signaling cascade that can affect various physiological processes.

Endocannabinoid Degradation and Regulation

Endocannabinoids are degraded by enzymes, such as FAAH and monoacylglycerol lipase (MAGL), which break down the endocannabinoids into inactive metabolites. The degradation of endocannabinoids is an important mechanism for regulating endocannabinoid signaling and preventing excessive activation of cannabinoid receptors.

The regulation of endocannabinoid degradation is a complex process that involves the action of various enzymes and proteins. For example, the enzyme FAAH is responsible for breaking down anandamide, while the enzyme MAGL is responsible for breaking down 2-AG. The regulation of endocannabinoid degradation is important for maintaining homeostasis and preventing disease. discomfort, or lack of focus than CBG alone.

How Your Endocannabinoid System Works: The Role of Cannabinoid Receptors

Unlike other signaling systems, the ECS operates “on demand.” Your body synthesizes endocannabinoids when they’re needed rather than storing them for later use. When something disrupts your internal balance—whether it’s pain, stress, or inflammation—endocannabinoids are produced to help restore equilibrium.

Exogenous cannabinoids can influence endocannabinoid signaling and various physiological processes, including neurogenesis in the hippocampus and reproductive processes during embryonic development.

Once an endocannabinoid binds to a cannabinoid receptor, it triggers specific cellular responses. After the message is delivered, enzymes break down the endocannabinoid to prevent overactivity.

According to a 2018 review published in the journal Neurotherapeutics, this system is involved in “regulating a variety of physiological and cognitive processes including fertility, pregnancy, pre- and postnatal development, various immune system functions, appetite, pain-sensation, mood, and memory.” The ECS exerts its influence through a complex interplay of receptors, enzymes, and signaling pathways, allowing for precise and localized control over these processes.

Functions of the Endocannabinoid System

The endocannabinoid system plays a crucial role in regulating various physiological processes, including pain, mood, appetite, sleep, and immune function. The endocannabinoid system is also involved in the regulation of neuronal excitability, synaptic plasticity, and neuroprotection.

The endocannabinoid system is further involved in the regulation of various diseases, including pain, inflammation, and neurodegenerative disorders. For example, the activation of CB1 receptors can reduce pain perception, while the activation of CB2 receptors can reduce inflammation.

Endocannabinoid System Deficiency: When Balance Is Disrupted

Research suggests that some health conditions may be linked to an endocannabinoid system that’s not functioning optimally. In 2004, Dr. Ethan Russo proposed the concept of Clinical Endocannabinoid Deficiency (CECD), suggesting that insufficient endocannabinoid levels or abnormal receptor function might contribute to various conditions.

Studies indicate that endocannabinoids impact dopamine release in the nucleus accumbens, thus enhancing the pleasurable aspects of eating and connecting the brain's reward system to appetite regulation. The nucleus accumbens plays a crucial role in modulating food-seeking behavior and pleasure related to food consumption.

A 2016 follow-up review in Cannabis and Cannabinoid Research found evidence supporting the CECD theory in conditions such as:

• Migraine
• Fibromyalgia
• Irritable bowel syndrome
• Post-traumatic stress disorder

The theory suggests that these conditions may respond to therapies that enhance ECS function, whether through lifestyle changes, dietary adjustments, or cannabinoid-based treatments. It is important to note that CECD is not universally recognized as a distinct clinical entity, and further research is needed to validate this concept and establish diagnostic criteria. While Dr. Russo’s work is foundational, ongoing research aims to clarify the role of ECS dysfunction in these conditions.

The ECS and Plant Interactions: Beyond Cannabis

Mango Cannabinoids: Nature's ECS Enhancers

While cannabis is the most well-known plant to interact with the ECS, other plants contain compounds that influence this system as well. Mangoes, for instance, contain myrcene, a terpene that may interact with the ECS.

Myrcene is believed to enhance the effects of certain cannabinoids by helping them cross the blood-brain barrier more efficiently. This explains why some people report that eating mangoes before cannabis consumption intensifies or prolongs the experience—though scientific evidence for this specific interaction remains limited.

Exogenous cannabinoids from mangoes can influence ECS functions by interacting with cannabinoid receptors, potentially affecting neurogenesis in the hippocampus and modulating reproductive processes during embryonic development.

Other foods that may support the ECS include:

• Omega-3 fatty acids (found in fish, flaxseeds, and walnuts): These provide the building blocks for endocannabinoid production. Consider incorporating sources of omega-3s in your diet to support endocannabinoid synthesis.
• Dark chocolate: Contains compounds that may inhibit the breakdown of anandamide.
• Black pepper and cloves: Contain beta-caryophyllene, which selectively binds to CB2 receptors.

Cannabis and Your ECS: A Complex Relationship

When cannabis enters your system, plant cannabinoids like THC and CBD interact with your endocannabinoid receptors, albeit in different ways:

• THC directly binds to CB1 receptors in your brain, which explains its psychoactive effects.
• CBD doesn’t bind directly to cannabinoid receptors but instead influences the ECS indirectly by inhibiting the FAAH enzyme that breaks down anandamide, potentially increasing its levels in the body.

Exogenous cannabinoids from cannabis interact with cannabinoid receptors to influence various biological processes, including mood, sleep, appetite, immune response, pain and inflammation.

How Long Does Cannabis Stay in Your System?

For those undergoing drug testing or concerned about the duration of cannabis effects, understanding how long cannabinoids remain detectable is important. The persistence of cannabis in your system depends on several factors:

• Frequency of use
• Metabolism
• Body fat percentage
• Hydration levels
• The type of test being used

Exogenous cannabinoids can be detected through various testing methods, influencing the results based on their interaction with cannabinoid receptors and endocannabinoid signaling.

According to research published in the journal Drug and Alcohol Dependence, here are general detection windows:

• Blood: 1-2 days for occasional users; up to 7 days for frequent users
• Saliva: 1-3 daysHair: Up to 90 days
• How long does cannabis stay in urine? This is the most common testing method, with detection times ranging from 3 days for single-use to 30+ days for heavy, chronic users

It’s crucial to remember that these are approximate detection windows, and individual results can vary significantly. Factors like the sensitivity of the testing method and individual metabolic rates play a key role. For more detailed information, consult a healthcare professional or toxicology expert.

When the ECS Goes Awry: Cannabinoid Hyperemesis Syndrome

While the ECS typically works to maintain balance, in some chronic cannabis users, a paradoxical condition called Cannabinoid Hyperemesis Syndrome (CHS) can develop. CHS is characterized by:

• Cyclic episodes of severe nausea and vomiting
• Abdominal pain
• Relief with hot showers or baths
• Symptoms that resolve with cannabis cessation

Exogenous cannabinoids may contribute to CHS by interacting with cannabinoid receptors, potentially leading to dysregulation of endocannabinoid signaling.

First described in medical literature in 2004, CHS appears to result from dysregulation of the ECS due to chronic, heavy cannabis use. The exact mechanism remains unclear, but researchers believe it may involve CB1 receptor downregulation or dysfunction in the digestive system’s ECS components.

A 2018 study in the journal Basic & Clinical Pharmacology & Toxicology suggests that CHS may be more common than previously thought, particularly as cannabis potency increases and consumption becomes more widespread. Recent research has also explored the role of transient receptor potential (TRP) channels in CHS pathophysiology, providing further insights into potential treatment strategies.

Supporting Your Endocannabinoid System Naturally

Whether you use cannabis or not, there are several evidence-based ways to support your ECS:

• Regular exercise: Studies show that physical activity increases endocannabinoid levels, particularly anandamide, which may contribute to the “runner’s high” phenomenon. Aim for at least 30 minutes of moderate-intensity exercise most days of the week to promote healthy ECS function.
• Stress reduction: Chronic stress can deplete endocannabinoids. Practices like meditation, yoga, and deep breathing can help maintain healthy ECS function.
• Quality sleep: Sleep deprivation disrupts ECS signaling. Prioritizing good sleep hygiene supports optimal endocannabinoid balance.
• Balanced diet: Foods rich in omega-3 fatty acids provide the precursors needed for endocannabinoid synthesis.
• Limit alcohol: Excessive alcohol consumption can impair ECS function, particularly in the brain.

Endogenous cannabinoids, also known as endocannabinoids, are naturally occurring, lipid-based neurotransmitters produced by the body. They play crucial roles in various bodily functions and are synthesized as needed, making it challenging to determine typical levels. Lifestyle factors like exercise and diet can significantly influence the levels and activity of these molecules within the endocannabinoid system (ECS).

The Future of ECS Research: Advances in Endocannabinoid Signaling

As our understanding of the endocannabinoid system grows, so does its potential as a therapeutic target. Researchers are exploring ECS-based treatments for conditions ranging from neurodegenerative diseases to metabolic disorders.

The potential therapeutic applications of exogenous cannabinoids are also being investigated, particularly in how they interact with cannabinoid receptors to influence neurogenesis in the hippocampus and modulate reproductive processes during embryonic development.

According to a 2019 review in the International Journal of Molecular Sciences, “The ECS represents a promising target in numerous pathological conditions, and its modulation may offer novel therapeutic approaches for many diseases that currently lack effective treatments.” Ongoing research is investigating novel ECS modulators, including compounds that selectively target specific receptors or enzymes, to develop more targeted and effective therapies.

Conclusion

The endocannabinoid system represents one of the most fascinating frontiers in modern medical research. From its role in maintaining homeostasis to its potential as a therapeutic target, the ECS continues to reveal new insights into human health and disease.

Endogenous cannabinoids, naturally occurring lipid-based neurotransmitters produced by the body, play crucial roles in various bodily functions and are synthesized as needed, making it challenging to determine typical levels. Exogenous cannabinoids interact with cannabinoid receptors to influence neurogenesis in the hippocampus and modulate reproductive processes during embryonic development, impacting endocannabinoid signaling and having potential implications in physiological and pathological conditions.

By understanding how this remarkable system works—and how various factors, including cannabis, affect it—we can make more informed decisions about our health and wellness strategies. Whether you’re curious about cannabis effects or simply interested in optimizing your body’s natural regulatory systems, the ECS deserves your attention as a key player in overall health.

This article is for informational purposes only and should not be considered medical advice. Always consult with a healthcare professional before starting any new health regimen or if you have concerns about your endocannabinoid system.

References

1. Maccarrone M, Bab I, Bíró T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends in Pharmacological Sciences. 2015;36(5):277-296. doi:10.1016/j.tips.2015.02.008

2. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Cannabis and Cannabinoid Research. 2016;1(1):154-165. doi:10.1089/can.2016.0009

3. Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. International Journal of Molecular Sciences. 2018;19(3):833. doi:10.3390/ijms19030833

4. Morales P, Reggio PH. An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. Cannabis and Cannabinoid Research. 2017;2(1):265-273. doi:10.1089/can.2017.0036

5. Mechoulam R, Parker LA. The Endocannabinoid System and the Brain. Annual Review of Psychology. 2013;64:21-47. doi:10.1146/annurev-psych-113011-143739

6. Pacher P, Bátkai S, Kunos G. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews. 2006;58(3):389-462. doi:10.1124/pr.58.3.2

7. Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iranian Journal of Psychiatry. 2012;7(4):149-156.

8. Huestis MA. Human cannabinoid pharmacokinetics. Chemistry & Biodiversity. 2007;4(8):1770-1804. doi:10.1002/cbdv.200790152

9. Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clinic Proceedings. 2012;87(2):114-119. doi:10.1016/j.mayocp.2011.10.005

10. Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid Hyperemesis Syndrome. Current Drug Abuse Reviews. 2011;4(4):241-249. doi:10.2174/1874473711104040241

11. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system. Neuroreport. 2003;14(17):2209-2211. doi:10.1097/00001756-200312020-00015

12. Meccariello R, Santoro A, D'Angelo S, et al. The Epigenetics of the Endocannabinoid System. International Journal of Molecular Sciences. 2020;21(3):1113. doi:10.3390/ijms21031113

13. Di Marzo V, Piscitelli F. The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics. 2015;12(4):692-698. doi:10.1007/s13311-015-0374-6

14. Silver RJ. The Endocannabinoid System of Animals. Animals. 2019;9(9):686. doi:10.3390/ani9090686

15. Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry. 2016;79(7):516-525. doi:10.1016/j.biopsych.2015.07.028

16. Lafourcade M, Larrieu T, Mato S, et al. Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nature Neuroscience. 2011;14(3):345-52. doi:10.1038/nn.2736.